ArQule, Inc. (Nasdaq: ARQL) announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE